A federal jury in Delaware has awarded Regeneron (NASDAQ:REGN) more than $400M in damages after finding that Amgen ...

In the long-running feud between Regeneron and Amgen around the companies’ competing PCSK9 cholesterol meds, Regeneron has ...

A federal jury in Delaware put US biotech major Amgen (Nasdaq: AMGN) on the hook Thursday for at least $271.2 million in ...

A federal jury in Delaware said on Thursday that biotech company Amgen owes competitor Regeneron more than $406 million for ...

Regeneron Pharmaceuticals won $406.8 million in damages for a lawsuit claiming Amgen violated antitrust and tort laws. A jury in a Delaware court found that Amgen violated certain laws, and gave ...

US Food and Drug Administration (FDA) in a calendar year, with this year set to break this record again, analysis suggests.

Federal court jury found Amgen liable for violating antitrust and tort laws by using cross-therapeutic bundled rebates to prevent Praluent® (alirocumab) from competing in the market Jury awarded ...

While M&A activity slowed in the first quarter of 2025, including in life sciences, there have been plenty of noteworthy developments in the ...

Some research has shown that dividend-paying stocks significantly outperformed their non-dividend-paying peers over the past ...